Objectives. The goal of this study was to dosimetrically compare 3-dimensional radiotherapy (3DCRT), intensity-modulated radiotherapy (IMRT), and helical tomotherapy (TOMO) plans for whole abdominopelvic radiotherapy (WART) in patients with gynecologic cancer.
Introduction
Whole abdominopelvic radiotherapy (WART) has been used as adjuvant treatment after staging laparotomy in gynecologic cancer, such as ovarian cancer, and endometrial cancer. Even though many studies have suggested that WART has possible benefits for patients with tumors in complete pathologic remission or minimal residual disease, there have been limitations in adopting one of the standard treatment modalities in gynecologic cancer. First, no randomized controlled trials have demonstrated that the addition of WART had positive clinical benefits for management of advanced ovarian cancer. In a small number of trials, WART and chemotherapy as adjuvant treatment have been compared (1) (2) (3) (4) (5) (6) (7) (8) (9) . Second, open-field Technology in Cancer Research & Treatment, Volume 8, Number 5, October 2009 technique has been conventionally preferred in WART in ovarian cancer patients whose abdominopelvic cavities need to be treated with radiotherapy. Acute and late treatmentrelated complications are found to be significant problems in some trials because conventional radiotherapy techniques have higher possibilities of radiation injury to dose-limiting organs such as the liver, kidneys, and small bowel.
Recently, high-precision radiotherapy has been applied to treat various types of cancer. IMRT is the one of the most advanced high-precision radiotherapy techniques that allows the delivery of increased tumor doses with relative sparing normal tissues compared to 3DCRT and conventional techniques. Several investigators have reported that whole pelvis IMRT and extended-field IMRT with BMS are feasible with safe and acceptable toxicities (10) (11) (12) . TOMO, a new methodology of IMRT, combines an intensity-modulated fan beam with the helical motion of the gantry relative to the patient. In a TOMO system, a 6-MV linac is mounted on a circular gantry that rotates in the transverse plane of the patient while the patient couch moves into the gantry bore. The fan beam is modulated by a binary MLC throughout the gantry rotation.
The goal of this study was to dosimetrically compare 3DCRT, IMRT, and TOMO plans in WART for patients with gynecologic malignancy.
Materials and Methods

Simulation Procedure and Target Delineation
We selected 10 patients with gynecologic cancer. Each patient underwent CT-based simulation with 5-mm-thick slice cuts in the supine position with the arms raised above the head. Intravenous and oral contrast agents were used in all patients.
Structures were manually contoured onto CT scan slices following the International Commission on Radiation Units and Measurements Report 50 recommendations. For all treatment planning modalities, GTV was defined as the gross tumor volume involved lymph nodes on CT images. Each clinical target volume (CTV) was separated for paraaortic lymph node (PALN), pelvis, and whole abdominopelvis (WA). CTV-PALN and CTV-pelvis generously covered para-aortic space, and pelvic lymph node regions (common, external, and internal iliac node), and pelvic floor with a 1.5 cm margin, respectively. The borders of CTV-WA extended from entire diaphragms to the inferior aspect of the obturator foramen, including liver, spleen, and both kidney. Laterally, the fields included the peritoneal reflection.
PTV-PALN, and PTV-pelvis were generated by expanding a 1 cm margin to account for setup uncertainty and respiratory organ movement. PTV-WA covered CTV-WA plus 1 cm margin in anterior-posterior, and left-right directions, 2 cm margin in superior-inferior direction. The liver, kidneys, spinal cord, lungs, heart, and BM were contoured on all CT images in which they were present as organs at risk (OARs).
Dose Prescription to Target Volumes, Constraints of OARs and Treatment Planning
Doses were prescribed to PTV as the followings: 30 Gy to PTV-WA, 40 Gy to PTV-PALN, 44 Gy to PTV-pelvis, and 50 Gy to GTV in 20 fractions (Table I) . Dose distributions for each plan were analyzed using dose-volume histograms.
Pinnacle planning system (Philips Medical Systems, Cleveland, OH) was used for 3DCRT treatment plans. Typical plans covered WA with anterior-posterior/posterior-anterior (AP/PA) ports. Each boost field was used to add each fractional dose for PALN, pelvis, and GTV with box technique. One-half value layer attenuation block was added to whole liver and kidney was blocked with PA field only.
Step-and-shoot IMRT treatment plans were generated using the Corvus planning system (CORVUS version 5.0, NOMOS Corporation, Sewickley, PA), and Siemens Primart 6-MV linac using static MLCs. To avoid the bias of arbitrary planning, the established two-isocenter technique was used; details of the protocol have been described elsewhere (13). Briefly, all patients but one had at least one field of length > 40 cm, thus requiring separate isocenters at the abdominal and pelvic regions. The two isocenters were placed 20 cm apart in the superior-inferior direction with the same left-right and anterior-posterior coordinates. Beams were placed approximately 70° apart at gantry angles of 255, 325, 180, 105, and 35°, and were arranged at identical gantry angles for both isocenters.
For each patient, TOMO treatment plan was made using Tomotherapy Hi-Art System, version 2.0 (TomoTherapy, Madison, WI). The prescribed dose was also 30 Gy to PTV-WA in 20 total fractions. Plans were normalized to the isocenter and dose was prescribed to the isodose level that encompassed 95% of the PTV, typically the 95% isodose. A field width of 5.04 cm, pitch of 0.172, and modulation factor of 2.0 were used in all TOMO plans. The grid resolution was 2 mm. Planning was performed with inhomogeneity corrections. The number of iterations was approximately 600. In IMRT and TOMO plans, the optimization goal was to minimize the dose to the kidneys, liver, and BM as well as achieving reasonable PTV coverage and acceptable PTV uniformity. No strict constraints were applied for optimization. Tolerated maximum doses to OARs had not to exceed the TD5/5 for each organ.
BMS was used in IMRT and TOMO but not 3DCRT. Therefore, a total of 5 plans were compared according to adoption of BMS: 3DCRT, IMRT without BMS, IMRT with BMS, TOMO without BMS, and TOMO with BMS.
Comparison Criteria Among Plans
Treatment plans were compared with dosimetric parameters for targets and OARs. The following criteria were used for evaluation of OAR doses, such as the liver, right and left kidneys, spinal cord, and BM:
1. Percent volume of each OAR receiving 5, 10, 20, 30, and 40 Gy (V 5 Gy , V 10 Gy , V 20 Gy , V 30 Gy , V 40 Gy ) 2. Maximum, minimum, and mean dose to each kidney and both kidneys together. Each PTV dose was estimated using the following parameters to evaluate target coverage: 
Mean PTV dose
Treatment times for 3DCRT, IMRT, and TOMO were calculated in each patient. Several assumptions were used to calculate treatment times for 3DCRT and IMRT. Elapsed time for isocenter set-up and rotating gantry between ports was presumed to be 120 and 20 seconds, respectively in 3DCRT. Elapsed time for changing segment within one treatment port in IMRT was presumed to be 10 seconds. Monitor unit was converted to treatment time by considering dose rate. Calculated treatment time by Tomotherapy Hi-Art System was adopted for TOMO treatment time.
Statistical Analysis
One-way analysis of variance (ANOVA) was used to compare dosimetric differences among plans. For pairwise comparisons among various techniques, a Bonferroni adjusted p value of 0.008 was considered to be significant to meet the overall significance level of <0.05. TOMO provided better dosimetric profile of target organs compared to 3DCRT and IMRT. Dosimetric analysis of PTV-WA showed no significant differences in V 107% and V 95% between IMRT with BMS and TOMO with BMS. However, D 95%, and D 05% of IMRT with BMS was significantly higher compared to TOMO with BMS (differences, 0.74 Gy, p= 0.04 and 7.3 Gy, p< 0.001). Even though mean doses were delivered more than prescribed dose in five plans, mean dose of TOMO with BMS was significantly lower than IMRT with BMS by 4.0 Gy (p< 0.001). Dosimetric parameters by 3DCRT showed significantly lower V 107% , V 95% , and D 95% values and higher D 05% and mean dose compared to IMRT with BMS and TOMO with BMS in paired t-test (Figure 4a ).
Results
No significant differences were observed in V 95% , and D 05% in analysis of PTV-PALN. V 107% , and D 95% was significantly higher in IMRT than TOMO (differences, 24.2%, p= 0.018 and 1.78 Gy, p= 0.003) and mean dose of TOMO was lower than IMRT by 2.0 Gy (p= 0.012) ( Figure 4b ). All dosimetric parameters of PTV-WP were higher in IMRT than TOMO. V 107% , and V 95% were higher in IMRT than TOMO (differences, 63%, p< 0.001 and 0.42%, p<0.001). IMRT had higher D 95% , and D 05% than TOMO (differences, 3.33 Gy, p< 0.001 and 2.82 Gy, p< 0.001). Mean dose of TOMO was lower than IMRT by 3.29 Gy (p< 0.001) (Figure 4c ). No significant differences were observed in V 107% , V 95% , D 95% , D 05%, and mean dose among the three plans (Figure 4d ).
TOMO also significantly reduced irradiated doses of OARs compared to IMRT. TOMO significantly reduced V 20Gy and mean dose of liver (differences, 26.5% and 6.02 Gy, respectively) (Figure 5a ). Dosimetric analyses of other OARs were similar to those of the liver: 25.9% and 3.66 Gy in the right kidney, 32.8% and 6.02 Gy in the left kidney, and 39.2% and 3.22 Gy in the spinal cord, respectively (Figure 5b, 5c, and  5d ). Dosimetric parameters of 3DCRT showed similar profiles with prescribed doses.
IMRT and TOMO with BMS reduced irradiated dose to BM as expected ( Figure 6 ). IMRT and TOMO with BMS significantly reduced V 10Gy of BM compared to IMRT and TOMO without BMS (differences, 2.87% and 2.65%, respectively). TOMO with BMS significantly spared V 30Gy and mean dose compared to IMRT with BMS (differences, 13.3% and 1.42 Gy, respectively). Even though BMS with IMRT and TOMO increase dose of some OARs, BMS technique did not impede coverage of PTV except mean dose of WA. IMRT and TOMO with BMS slightly increased mean dose of WA by 0.13 Gy and 0.56 Gy compared to IMRT and TOMO without BMS (p=0.048 and 0.003, respectively). Even though the use of BMS was impossible in 3DCRT, there was no difference of V 20Gy but considerably high V 30Gy compared to IMRT and TOMO.
Estimated treatment times for 3DCRT, IMRT, and TOMO are listed in Table II . IMRT showed significantly longer treatment time than TOMO irrespective of BMS (p< 0.001). No significant differences in each mean treatment time were observed according to BMS with IMRT and TOMO plans.
Discussion
Radiotherapy, as a consolidation therapy, includes the entire abdominopelvis in ovarian cancer patients with no or minimal residual volume. Malignant cells may exfoliate into the peritoneal cavity, and then flow to the right paracolic gutter and undersurface of the right hemidiaphragm. The omentum is also a frequent site of implantation of tumor cells. Clinical data showed that pelvic radiotherapy was insufficient because of the higher rate of upper abdominal failure (14) (15) (16) . Although open-field technique has been adopted in most hospitals, gynecologic oncologists have hesitated to use WART because incidence of late toxicity of small bowel may reach to 10% (17). Even though intraperitoneal therapeutic approaches such as intraperitoneal chromic phosphate ( 32 P), radioimmunotherapy, and intraperitoneal chemotherapy have been conducted for consolidation therapy for the entire abdominopelvis, theoretical and practical advantages WART over intraperitoneal approaches are suggested as the followings; mainly a more homogeneous dose distribution, better coverage of the pelvic and para-aortic lymph nodes, and the ability to treat all the peritoneal surfaces without limitations from the presence of postoperative adhesions (18). Ultimately, newer radiotherapeutic modalities will be required for safe and effective delivery of WART.
TOMO is demonstrated to provide dosimetric superiority to static IMRT and 3DCRT in various types of cancers. Dosimetric comparisons showed that TOMO achieved better conformity index, dose homogeneity index, and dose gradient score index for target coverage. In addition, irradiated dose to OARs was significantly reduced compared to static IMRT and 3DCRT (19, 20) . TOMO makes it possible to enhance radiation dose in high-risk areas using simultaneous integrated boost technique without additional exposure of normal tissue. These advantages considered, TOMO seems to be the candidate to deliver safe and effective WART for ovarian cancer (21, 22) .
When dosimetric profiles are compared among 3DCRT, IMRT, and TOMO in WART, 3DCRT has several limitations. Forward treatment planning makes it difficult to achieve proper target coverage with sufficient sparing OARs like BM. In addition, to treat multiple targets, it is inevitable to prolong treatment period through several cone downs or to lengthen fractional treatment time using multiple boost fields to targets. The superiority of IMRT and TOMO to 3DCRT results from inverse treatment planning and simultaneous integrated boost. Of these high precision radiotherapeutic modalities, TOMO has suitable dosimetric advantages over IMRT in WART. Delivering an intensity-modulated fan beam with the helical motion of the gantry, the former provides dosimetric advantages in WART.
Our data demonstrated the dosimetric superiority of TOMO compared to 3DCRT and IMRT. Five dosimetric parameters, V 107% , V 95% , D 95% , D 05% , and mean dose, were used in analysis of target coverage. 3DCRT had different dosimetric profiles compared to IMRT and TOMO. Because of use of liver and kidney block, 3DCRT was insufficient to cover PTV-WA on analysis of dosimetric parameters. Irradiated dose to PTV-WA was lower than prescribed dose. However, higher mean dose than 30 Gy reflected irradiated doses of other target volumes that exceeded the prescribed dose to PTV-WA. IMRT and TOMO had similar dosimetric profiles. However, IMRT had excessive hot points, because it had difficulty in covering cylindrical-shaped WA and other target volumes with fixed gantry angles. Above all, due to the inevitable use of two isocenters with 10 ports to cover WA field, clinical application of WART using IMRT seems to be difficult. TOMO showed the best dosimetric profile to cover WA and other target volumes and afforded the best approach to each prescribed dose with relatively little excessive doses. In patients with gynecologic malignancy, IMRT reduces the irradiated dose of BM in whole pelvic radiotherapy and extended-field radiotherapy in dosimetric analysis. In our data, IMRT and TOMO made differences of irradiated dose to BM according to BMS. However, TOMO showed significantly superior BM sparing effect to IMRT. In addition, BMS showed no disturbance in saving OARs, covering PTV, in addition to no prolonging treatment time. Non-BM sparing whole pelvic IMRT and concurrent chemotherapy had less hematologic toxicity and fewer chemotherapy interruptions compared to patients with conventional whole pelvis irradiation and concurrent chemotherapy (10, 23). Mell et al., showed that increased pelvic BM V 10 was associated with acute hematologic toxicity in patients undergoing concurrent chemoradiotherapy (24). Extended-field IMRT with concurrent weekly chemotherapy was associated with low incidence of Grade 3 or higher hematologic toxicity without analysis of BM volume (11, 12, 21, 25) . The question still remains whether these dosimetric advantages may translate into clinical benefits. Further studies can answer whether BM sparing extended-field IMRT with concurrent chemotherapy reduces hematologic toxicity. There has been no published data about BM sparing whole abdominopelvic IMRT until now. Our data showed that BM sparing whole abdominopelvic TOMO results in the reduction of BM volume irradiated above 30 Gy and mean BM dose compared to IMRT and 3DCRT. However, BM is known to significantly change at 10 Gy including dilated sinusoids, acute hemorrhage, and the reduction of precursor cells (26). It also remains unanswered whether the dosimetric benefit of BM sparing using TOMO is associated with lower hematologic toxicity in WART. Even though there is no available clinical data, the addition of concurrent chemotherapy to WART may have more toxic effects than WART alone.
Treatment times were compared among 3DCRT, IMRT, and TOMO. For 3DCRT and IMRT, time taken for isocenters set-up and moving gantry between ports were considered. In addition, time taken for changing segment was estimated in IMRT. For treating four target volumes in one fraction, 3DCRT used 4-5 isocenters and 10-18 treatment ports. It takes approximately 17 minutes for one fraction that cannot be accepted as 3DCRT. Although IMRT achieved comparative covering target volumes and sparing OARs to TOMO, IMRT inevitably uses two isocenters to treat whole AP with five treatment ports per center in most cases. The technique using two isocenters may generate several problems in clinical application to WART. First, it takes almost one hour for one fraction that cannot be tolerable to both patient and radiation oncologist. Second, the dosimetric problem of gap junction between the upper and lower fields cannot be clarified. So far, it seems to be impractical to treat WART using IMRT in patients with ovarian cancer. In TOMO treatment, it takes about 5 minutes to daily verify patient set-up with Megavoltage CT scan, and 12.7 minutes to treat WART using TOMO. In addition to superior covering target and sparing OARs, acceptable treatment time is another merit of TOMO for clinical application of WART.
In our dosimetric analysis of WART, our data demonstrates that TOMO provides the most excellent coverage of targets, sparing normal organs such as the liver, kidneys, and BM, and acceptable treatment time compared to 3DCRT and IMRT. We suggest that WART using TOMO is feasible in ovarian cancer patients. 
